Associated Papers
Functional characterization of all CDKN2A missense variants and comparison to in silico models of pathogenicity.
Kimura H et al.
Elife, 2025
40238651 (PubMed )
Supplement: elife-95347-supp2.xlsx › Appendix_1-table_2
Functional characterization of all CDKN2A missense variants and comparison to in silico models of pathogenicity.
Kimura H et al.
Biorxiv : the Preprint Server for Biology, 2025
38234851 (PubMed )
Supplement: media-2.pdf
Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.
Pantaleo A et al.
Cancers, 2023
38201484 (PubMed )
Supplement: cancers-16-00056-s001.zip › Table_S3_Proof_final_version.xlsx › ATM_
CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM et al.
Frontiers in Endocrinology, 2023
37964967 (PubMed )
Supplement: Table_1.xlsx › Table_S3
Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation.
Wang J et al.
Oncotarget, 2016
27144525 (PubMed )
Supplement: oncotarget-07-29901-s001.xlsx › SupplementalTable1_SNV
Patterns of genetic alterations in pancreatic cancer: a pooled analysis.
Blanck HM et al.
Environmental and Molecular Mutagenesis, 1999
Select a paper to view details